Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

被引:45
|
作者
Genant, Harry K. [1 ,2 ]
Libanati, Cesar [3 ]
Engelke, Klaus [4 ,5 ]
Zanchetta, Jose R. [6 ]
Hoiseth, Arne [7 ]
Yuen, Chui Kin [8 ]
Stonkus, Sigtas [9 ]
Bolognese, Michael A. [10 ]
Franek, Edward [11 ,12 ]
Fuerst, Thomas [13 ]
Radcliffe, Hoi-Shen [14 ]
McClung, Michael R. [15 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Synarc Inc, San Francisco, CA 94105 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Univ Erlangen Nurnberg, Inst Med Phys, D-91052 Erlangen, Germany
[5] Synarc Inc, Hamburg, Germany
[6] Inst Invest Metab, Buenos Aires, DF, Argentina
[7] Curato Rentgen, Oslo, Norway
[8] SIGMA Canadian Menopause Soc, Vancouver, BC V6H 1E5, Canada
[9] Klaipeda Univ Hosp, LT-92228 Klaipeda, Lithuania
[10] Bethesda Hlth Res, Bethesda, MD 20879 USA
[11] Cent Clin Hosp MSWiA, PL-02507 Warsaw, Poland
[12] Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland
[13] Synarc Inc, Newark, CA 94560 USA
[14] Amgen Ltd, Cambridge CB4 OWD, England
[15] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
关键词
Bone mineral density; Bone mineral content; Denosumab; Hip; Osteoporosis; Quantitative computed tomography; QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; NONINVASIVE ASSESSMENT; FRACTURES; TURNOVER; STRENGTH; ALENDRONATE; PHASE-2; AMG-162;
D O I
10.1016/j.bone.2013.07.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by -1.5% and -2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to <0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. (C) 2013 The Authors. Published by Elsevier Inc All rights reserved.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 50 条
  • [21] Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis
    Lesley J. Scott
    Drugs & Aging, 2014, 31 : 555 - 576
  • [22] The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
    Papapoulos, S.
    Lippuner, K.
    Roux, C.
    Lin, C. J. F.
    Kendler, D. L.
    Lewiecki, E. M.
    Brandi, M. L.
    Czerwinski, E.
    Franek, E.
    Lakatos, P.
    Mautalen, C.
    Minisola, S.
    Reginster, J. Y.
    Jensen, S.
    Daizadeh, N. S.
    Wang, A.
    Gavin, M.
    Libanati, C.
    Wagman, R. B.
    Bone, H. G.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (12) : 2773 - 2783
  • [23] Trabecular and Cortical Microarchitecture in Postmenopausal HIV-Infected Women
    Yin, Michael T.
    Shu, Aimee
    Zhang, Chiyuan A.
    Boutroy, Stephanie
    McMahon, Donald J.
    Ferris, David C.
    Colon, Ivelisse
    Shane, Elizabeth
    CALCIFIED TISSUE INTERNATIONAL, 2013, 92 (06) : 557 - 565
  • [24] Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis
    von Keyserlingk, Camilla
    Hopkins, Robert
    Anastasilakis, Athanasios
    Toulis, Konstantinos
    Goeree, Ron
    Tarride, Jean-Eric
    Xie, Feng
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (02) : 178 - 186
  • [25] Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
    Anastasilakis, A. D.
    Toulis, K. A.
    Goulis, D. G.
    Polyzos, S. A.
    Delaroudis, S.
    Giomisi, A.
    Terpos, E.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 721 - 729
  • [26] Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
    Miller, P. D.
    Pannacciulli, N.
    Brown, J. P.
    Czerwinski, E.
    Nedergaard, B. S.
    Bolognese, M. A.
    Malouf, J.
    Bone, H. G.
    Reginster, J. -Y.
    Singer, A.
    Wang, C.
    Wagman, R. B.
    Cummings, S. R.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (08) : 3163 - 3170
  • [27] Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis
    Takada, Junichi
    Katahira, Genichiro
    Iba, Kousuke
    Yoshizaki, Takashi
    Yamashita, Toshihiko
    JOURNAL OF BONE AND MINERAL METABOLISM, 2011, 29 (04) : 458 - 465
  • [28] Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
    Macdonald, H. M.
    Nishiyama, K. K.
    Hanley, D. A.
    Boyd, S. K.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (01) : 357 - 362
  • [29] Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis
    Zhou, Zhenyu
    Chen, Chen
    Zhang, Jun
    Ji, Xinran
    Liu, Lifeng
    Zhang, Guichun
    Cao, Xuecheng
    Wang, Pingshan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (05): : 2113 - 2122
  • [30] Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis
    Okawa, Tokutaro
    Okawa, Motomi
    Koike, Tatsuya
    JOURNAL OF BONE AND MINERAL METABOLISM, 2022, 40 (06) : 960 - 967